New targeted therapy may treat many types of cancer in adults and children
A new targeted therapy, larotrectinib (LOXO-101), may be the first targeted cancer medicine taken by mouth that is not specific to a certain cancer type, but instead focuses on a specific genetic abnormality found in a range of tumor types. Larotrectinib stops tropomyosin receptor kinase (TRK) fusion proteins. Researchers reviewed data from 3 early clinical trials that involved 43 adults and 12 children with over 17 types of cancer, including specific types of colon, lung, pancreatic, thyroid, salivary gland, and gastrointestinal cancers, as well as melanoma and sarcoma. Results indicate that larotrectinib may be a new treatment option in both adults and children for a variety of cancers that have TRK fusion proteins.